Holiday to Set Tone...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$7.74 -0.01 | -0.13%
05/22/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 7.75 |
| 52 Week High | 11.36 |
| 52 Week Low | 5.42 |
| Avg. Daily Vol. (Mil) | 1.03 |
| Beta (3 year) | 2.07 |
| Share Related Items | |
| Mkt Cap (Mil) | 748.31 |
| Shares Out (Mil) | 96.56 |
| Float (Mil) | 56.47 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 13.00 |
| Current Ratio | 14.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.34K |
| Price/Book | 3.84 |
| Price/Cash Flow | -15.40 |
| Per Share Data | |
| Earnings | -0.64 |
| Sales | 0.00 |
| Book Value | 2.02 |
| Cash Flow | -0.50 |
| Business Summary | |
|---|---|
| Achillion Pharmaceuticals, Inc. is a biopharmaceutical Company which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. | |
| General Information | |
| 300 George Street
New Haven, CT 06511 |
|
| www.achillion.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 56 | |
| CEO: Michael D. Kishbauch | |
| Short Interest | |
| Current Month (Mil) | 13.08 |
| Previous Month (Mil) | 12.70 |
| Short Interest Ratio (Days) | 10.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -24.20 |
| Return on Investments | -25.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- UserMy Watch List
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
Latest ACHN Headlines from TheStreet
- Achillion Initiates Phase 2 Interferon-Free Trial Of Sovaprevir And ACH-3102 For Genotype 1 HCV 04.16.13 | 06:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Achillion To Present At Two Upcoming Investor Conferences 03.01.13 | 06:03 am
- Achillion Pharmaceuticals Announces Closing Of Public Offering 02.27.13 | 04:02 pm
- Achillion Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock 02.21.13 | 08:02 pm
- Achillion Reports 2012 Fourth Quarter And Year-End Financial Results 02.20.13 | 04:02 pm
- Achillion Pharmaceuticals Announces Proposed Public Offering Of Common Stock 02.20.13 | 04:02 pm
- Achillion To Report Fourth Quarter And Year End 2012 Financial Results And Host Conference Call On February 20, 2013 02.19.13 | 04:02 pm
- Achillion To Present At The 2013 Leerink Swann Global Healthcare Conference 02.08.13 | 06:02 am
- Achillion To Present At The Noble Financial Capital Markets' Ninth Annual Equity Conference 01.17.13 | 06:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- Cramer's Mad Money - 8 Things To Watch In The Week Ahead (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- Achillion Pharma draws bullish bet - NASDAQ 09.25.12 | 04:09 pm
- 3 Stocks Upgraded On September 19 To Consider - Seeking Alpha 09.21.12 | 10:09 am
- Morning Market Movers - Benzinga 09.19.12 | 09:09 am
- REVEALED: New Analyst Stock Coverage to Assess Today - Wall St. Cheat Sheet 06.13.12 | 04:06 am
- Stock Insights: Achillion Pharmaceuticals, DG FastChannel, Tempur Pedic, Iron Mountain, Nasdaq OMX June 7th - Wall St. Cheat Sheet 06.07.12 | 10:06 am
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
